[
  {
    "ts": "2025-10-16T17:18:39+00:00",
    "headline": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism",
    "summary": "Amgen (AMGN) is making waves after its VESALIUS-CV Phase 3 trial demonstrated that Repatha significantly lowers major cardiovascular events in at-risk patients who have not had a prior heart attack or stroke. Adding to this momentum, Amgen introduced AmgenNow, a new direct-to-patient program. The initiative makes Repatha available at a much lower cash price, aiming to broaden access and potentially increase future uptake among patients. See our latest analysis for Amgen. Amgen's momentum has...",
    "url": "https://finance.yahoo.com/news/look-amgen-amgn-valuation-repatha-171839680.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e182eee8-55d3-33aa-a836-be8aeaa5906d",
      "content": {
        "id": "e182eee8-55d3-33aa-a836-be8aeaa5906d",
        "contentType": "STORY",
        "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism",
        "description": "",
        "summary": "Amgen (AMGN) is making waves after its VESALIUS-CV Phase 3 trial demonstrated that Repatha significantly lowers major cardiovascular events in at-risk patients who have not had a prior heart attack or stroke. Adding to this momentum, Amgen introduced AmgenNow, a new direct-to-patient program. The initiative makes Repatha available at a much lower cash price, aiming to broaden access and potentially increase future uptake among patients. See our latest analysis for Amgen. Amgen's momentum has...",
        "pubDate": "2025-10-16T17:18:39Z",
        "displayTime": "2025-10-16T17:18:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-amgen-amgn-valuation-repatha-171839680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-amgen-amgn-valuation-repatha-171839680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T12:00:12+00:00",
    "headline": "Amgen (NASDAQ:AMGN) Seems To Use Debt Quite Sensibly",
    "summary": "Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",
    "url": "https://finance.yahoo.com/news/amgen-nasdaq-amgn-seems-debt-120012477.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "74512de4-84c0-3ac4-bb9f-8b13564d3c29",
      "content": {
        "id": "74512de4-84c0-3ac4-bb9f-8b13564d3c29",
        "contentType": "STORY",
        "title": "Amgen (NASDAQ:AMGN) Seems To Use Debt Quite Sensibly",
        "description": "",
        "summary": "Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",
        "pubDate": "2025-10-16T12:00:12Z",
        "displayTime": "2025-10-16T12:00:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-nasdaq-amgn-seems-debt-120012477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-nasdaq-amgn-seems-debt-120012477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T05:59:14+00:00",
    "headline": "Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is a California-based biopharmaceutical company. On October 3, Op⁠penheimer reaffirm‍ed its‌ O‌utpe‍rform ratin‌g on Amgen Inc. (NASDAQ:AMGN) with a price target of $​380. The‌ firm high‌lighted Amgen’s solid performance and al‌so repor⁠ted tha‌t‌ its VESALIUS-CV trial reached […]",
    "url": "https://finance.yahoo.com/news/oppenheimer-highlights-amgen-amgn-strong-055914635.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "e5a8ff57-dabd-3cc1-9ff7-2c80cc0be9e6",
      "content": {
        "id": "e5a8ff57-dabd-3cc1-9ff7-2c80cc0be9e6",
        "contentType": "STORY",
        "title": "Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is a California-based biopharmaceutical company. On October 3, Op⁠penheimer reaffirm‍ed its‌ O‌utpe‍rform ratin‌g on Amgen Inc. (NASDAQ:AMGN) with a price target of $​380. The‌ firm high‌lighted Amgen’s solid performance and al‌so repor⁠ted tha‌t‌ its VESALIUS-CV trial reached […]",
        "pubDate": "2025-10-16T05:59:14Z",
        "displayTime": "2025-10-16T05:59:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a8ba76827d6ac52cc8d6c3f02ee33494",
          "originalWidth": 1920,
          "originalHeight": 1440,
          "caption": "Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cLbYCdtOoj120Uelo9cGKA--~B/aD0xNDQwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/a8ba76827d6ac52cc8d6c3f02ee33494.cf.webp",
              "width": 1920,
              "height": 1440,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9Erk37dyXrImJWmhBWRSQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a8ba76827d6ac52cc8d6c3f02ee33494.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/oppenheimer-highlights-amgen-amgn-strong-055914635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/oppenheimer-highlights-amgen-amgn-strong-055914635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]